Jul 4, 2019
MediSieve Team is Growing
Over this year MediSieve has grown from a four-people start-up into a diverse team of professionals with various expertise.
LONDON – July 04, 2019 – Joining the MediSieve team as associate biochemists are Lucy Moran ,Ana Skelton-Garcia, Manishankar Chellappan and Silvia Prelez, while Dr Kerstin Stegmann joins the technical management team as an immunologist. They will work together to develop, test, and validate our magnetic particle products, focused on Sepsis.
A QA/RA Analyst (Jon Kelly) and Marketing Analyst (Alina Kagermazova) have also joined to support MediSieve's push towards commercial success.The study met all primary and secondary endpoints, with all results indicating that the System used in the trial is safe and well tolerated. No serious adverse events were reported, and no difference was observed between genders.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
